West Synchrony™ Prefillable Syringe System Launches at CPHI: Redefining a system-level solution for drug delivery

Rhea-AI Summary

West Pharmaceutical Services (NYSE: WST) launched the West Synchrony™ Prefillable Syringe (PFS) System at CPHI Worldwide and said the system will be commercially available in January 2026. The system is described as a fully verified, system-level solution for biologics and vaccines that provides a single design verification and characterization package, a single system-level drug master file and regulatory package, and single-source supply options with make-to-stock and make-to-order and low minimum order quantities.

Management positioned the offering as intended to streamline syringe selection, accelerate regulatory submissions, and secure supply chains, while also cautioning that forward-looking statements contain risks and that there is no certainty the product will achieve particular results.

Positive

• Commercial availability set for January 2026
• Fully verified system-level solution for biologics and vaccines
• Single system-level drug master file and regulatory package
• Single-source supply with make-to-stock and low minimums

Negative

• Company states no certainty Synchrony will achieve any particular result
• Risk from dependence on third-party suppliers and partners
• Supply-chain interruptions or weaknesses could affect delivery

EXTON, Pa., Oct. 27, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the launch of its West Synchrony™ Prefillable Syringe (PFS) System at CPHI Worldwide in Frankfurt, Germany. This innovative system marks a significant shift in drug delivery solutions by offering a fully verified platform from a single supplier that will be commercially available in January 2026.

The West Synchrony PFS system delivers a fully verified system-level solution designed specifically for biologics and vaccines. It sets a new standard in drug delivery by accelerating syringe selection through its comprehensive performance and regulatory data packages.

"Leaders in drug development face pressures to meet milestones efficiently amid complex challenges, amongst them, selecting prefillable syringes. They currently rely on fragmented approaches—assembling component data from multiple suppliers or outsourcing piecemeal verification, which risks delays, increased costs and regulatory setbacks," said Andy Polywacz, President of Integrated Systems at West. "With West Synchrony prefillable syringe system, it enables pharmaceutical companies to streamline design, accelerate regulatory submission, and secures a reliable supply chain for combination products that meets quality and volume needs."

Key benefits of the West Synchrony PFS system include:

• Design and System-Level Performance: a single design verification and characterization package from West ensures the form, fit and function of the entire PFS system.
• Regulatory Ease with Comprehensive Submission: a streamlined submission process with one system-level drug master file and regulatory package tailored for comprehensive regulatory needs.
• Single Source Supply: single supplier approach, offering make-to-stock and make-to-order supply with low minimum order quantities, ensuring reliability and flexibility.

For more information about West Synchrony PFS system, click here.

For more information about CPHI Worldwide, click here.

Forward-Looking Statements
Certain forward-looking statements are included in this press release. They use words such as "standard," "streamline," "accelerate," "secures," "reliable," "meets," and other similar terminology. These statements reflect management's current expectations regarding future events and operating performance and speak only as of the date of this release. There is no certainty that actual results will be achieved in-line with current expectations. Specifically, there is no certainty that West's introduction of the Synchrony PFS system will achieve any particular result.  These forward-looking statements involve a number of risks and uncertainties. Various factors could cause the actual results to differ materially from those expressed in, or underlying, these forward-looking statements, such as customers' changing inventory requirements and manufacturing plans; customer decisions to move forward with new products and product categories; average profitability, or mix, of the products offered for sale; dependence on third party suppliers and partners; interruptions or weaknesses in the supply chain; increased raw material costs; fluctuations in currency exchange; and the ability to meet development milestones with key customers. These important factors are not all inclusive. For a description of certain additional factors that could cause West's future results to differ from those expressed in any such forward-looking statements, see Item 1A, entitled "Risk Factors," in West's Annual Report on Form 10-K for the year ended December 31, 2024. Except as required by law or regulation, West undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

About West 
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.

Headquartered in Exton, Pennsylvania, West in its fiscal year 2024 generated $2.89 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com. 

All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/west-synchrony-prefillable-syringe-system-launches-at-cphi-redefining-a-system-level-solution-for-drug-delivery-302594561.html

SOURCE West Pharmaceutical Services, Inc.

FAQ

What is the West Synchrony PFS system announced by West (WST) on October 27, 2025?

A fully verified prefillable syringe system for biologics and vaccines with system-level verification and regulatory documentation.

When will West Synchrony PFS be commercially available for WST customers?

West said the Synchrony PFS system will be commercially available in January 2026.

How does the West Synchrony PFS system affect regulatory submissions for WST customers?

It offers a single system-level drug master file and regulatory package intended to streamline submissions.

Does the West Synchrony PFS system offer supply flexibility for WST buyers?

Yes; West offers a single-source approach with make-to-stock and make-to-order options and low minimum order quantities.

What risks did West (WST) cite about the Synchrony PFS launch on October 27, 2025?

Management warned there is no certainty of specific results and cited risks like supplier dependence and supply-chain interruptions.